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Background: There are currently no serum biomarkers capable of distinguishing elevations in serum alanine
aminotransferase (ALT) that portend serious liver injury potential from benign elevations such as those occurring
during cholestyramine treatment. The aim of the research was to test the hypothesis that newly proposed
biomarkers of hepatotoxicity would not significantly rise in serum during elevations in serum ALT associated with
cholestyramine treatment, which has never been associated with clinically relevant liver injury.
Methods: In a double-blind placebo-controlled trial, cholestyramine (8g) was administered for 11 days to healthy
adult volunteers. Serum from subjects with elevations in alanine aminotransferase (ALT) exceeding three-fold the
upper limit of normal (ULN) were utilized for biomarker quantification.
Results: In 11 of 67 subjects, cholestyramine treatment resulted in ALT elevation by >3x ULN (mean 6.9 fold; range
3–28 fold). In these 11 subjects, there was a 22.4-fold mean increase in serum levels of miR-122 relative to baseline,
supporting a liver origin of the serum ALT. Significant elevations were noted in mean levels of necrosis biomarkers
sorbitol dehydrogenase (8.1 fold), cytokeratin 18 (2.1 fold) and HMGB1 (1.7 fold). Caspase-cleaved cytokeratin 18, a
biomarker of apoptosis was also significantly elevated (1.7 fold). A rise in glutamate dehydrogenase (7.3 fold) may
support mitochondrial dysfunction.
Conclusion: All toxicity biomarkers measured in this study were elevated along with ALT, confirming the liver
origin and reflecting both hepatocyte necrosis and apoptosis. Since cholestyramine treatment has no clinical liver
safety concerns, we conclude that interpretation of the biomarkers studied may not be straightforward in the
context of assessing liver safety of new drugs.
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Hepatotoxicity is a major reason for termination of clinical
drug development programs and regulatory actions on
drugs, including withdrawal from the market. The poten-
tial for a new drug candidate to cause clinically important
liver injury is often difficult to ascertain in clinical trials
due to deficiencies in the currently available serum tests,
which have not changed in more than four decades. The
most sensitive and widely employed serum test for liver* Correspondence: pwatkins@thehamner.org
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unless otherwise stated.injury is serum alanine aminotransferase (ALT). However,
there are drugs that cause serum ALT elevations, even
pronounced elevations, that do not cause clinically im-
portant liver injury [1]. To address this issue, the current
FDA guidance for evaluation of drug-induced liver injury
(DILI) in clinical trials recommends continuing treatment
of subjects with asymptomatic ALT elevations (up to 8 ×
ULN) to determine whether there is subsequent loss of
liver function, specifically with concurrent elevation of
serum bilirubin (“Hy’s Law” criteria) [2]. However, this
practice may be placing clinical trial participants at risk.
There exists at least one example of a patient in a clinical
trial who developed fatal liver failure despite discontinuing
treatment with the implicated drug prior to the occur-
rence of elevation in serum bilirubin [3].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The study design. Subjects were administered placebo
from day 1 to 12 of the study or placebo from day 1 to 12 and
single dose 400 mg Moxifloxacin (Moxi) on day 12, followed by a
washout phase with cholestyramine from day 13 to 23.
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to cause clinically important liver injury, it has been as-
sumed that the underlying mechanisms may not involve
hepatocellular damage. Proposed mechanisms include
extrahepatic sources of the ALT, leak of ALT from
healthy hepatocytes, increased ALT synthesis within the
liver, and/or reduced ALT clearance from blood. New
serum biomarkers have been proposed to detect liver
specific injury (miR-122), apoptosis (caspase cleaved
cytokeratin-18 fragments), and necrosis (sorbitol de-
hydrogenase, full-length cytokeratin-18, glutamate de-
hydrogenase and HMGB1) [4-9]. It is a reasonable
hypothesis that these new biomarkers may help distin-
guish between benign ALT elevations and those that
portend potential for clinically important liver injury.
Cholestyramine, a cholesterol lowering drug, is an or-
ally administered and non-absorbable ion-exchange resin
that binds bile acids in the intestine, interrupting their
enterohepatic circulation and increasing their fecal ex-
cretion [10]. Cholestyramine is also sometimes used to
interrupt enterohepatic circulation of certain drugs and
to accelerate their removal from the body [10,11]. To
our knowledge, and in spite of the very large clinical ex-
perience with cholestyramine during decades of use,
there have not been reports of clinically important hep-
atotoxicity associated with this treatment. Indeed, chole-
styramine is commonly used in patients with advanced
liver disease to relieve symptoms associated with chole-
stasis [12]. However, in at least two clinical studies cho-
lestyramine treatment was reported to be associated
with elevations in serum ALT [13,14].
In a clinical study involving treatment of healthy adult
volunteers with cholestyramine, we observed asymptom-
atic elevations in serum ALT. This discrepancy between
traditional interpretation of serum ALT and clinical
safety experience raises the possibility that cholestyramine-
associated elevations in serum ALT do not reflect true
hepatocyte injury. To provide insight into mechanisms
underlying these benign elevations of serum ALT, we
assayed serum samples from subjects who experienced
serum ALT elevations during treatment with cholestyr-
amine for the liver specific microRNA, miR-122, and
for biomarkers associated with necrosis and apoptosis.
Our hypothesis was that these biomarkers would not
demonstrate concomitant elevations with the serum
ALT and may therefore be useful in clinical settings to
distinguish benign elevations in serum ALT from those




The subjects studied were a subset of a larger random-
ized, double blind, phase-I clinical trial conducted inhealthy male and female subjects aged 18–65 years old
in order to evaluate the potential for an active investiga-
tional new drug to prolong the QT interval. After a 12
day treatment phase (active drug or placebo), all subjects
(including those randomized to placebo) entered a
“washout” phase involving treatment with cholestyr-
amine (8g powder, three times a day taken orally in a
glass of fruit juice, milk soup or water, for 11 days, i.e.,
from day 13 to 23 of the clinical trial) or activated char-
coal to accelerate the elimination of the investigational
drug (in those that received active drug). The 67 subjects
involved in the current study were all randomized to re-
ceive placebo during the treatment phase, never received
the active drug, and only received cholestyramine during
the washout phase. Thirty-four of these placebo treated
subjects also received a single oral dose of moxifloxacin
(positive control for QT prolongation), on the day before
the start of cholestyramine treatment. The study proto-
col is shown in Figure 1. A complete description of the
clinical trial has been included in CONSORT flow chart
(Additional file 1) and CONSORT checklist (Additional
file 2: Table S1).
Serial blood samples were obtained and serum en-
zymes (ALT, AST, and ALP) and total bilirubin were
assayed before (baseline) and during the cholestyramine
treatment period using AU 400 Olympus clinical chem-
istry analyzer at the Department de Biologie Clinique
Centre régional de lutte contre le Cancer Eugene
Marquis, Rennes Cedex, France. Samples were archived
only from subjects who experienced confirmed ALT >3
times the ULN; only the baseline and the serum sample
with the peak ALT value was archived from these sub-
jects and available for biomarker analysis. The study
protocol was reviewed and approved by the regional eth-
ics committee, CPP OUEST VI, at the Centre Hospita-
lier Universitaire Cavale Blanche, Brest Cedex, France.
The clinical trial was conducted in accordance with the
International Conference of Harmonisation Guidelines
for Good Clinical Practice and the Declaration of
Helsinki. Written informed consent was obtained from
all subjects prior to the study.
Only samples from subjects treated with cholestyr-
amine after receiving placebo during the active treat-
ment phase were analyzed in this study (i.e., no subjects
studied received the investigational drug at any time).
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Analysis was performed on baseline serum samples and
the single serum samples containing the highest value
for ALT level (i.e., the only post-baseline serum sample
archived and therefore available for analysis). Serum
concentrations of glutamate dehydrogenase (GLDH;
Randox Laboratories, Kearneysville, WV) and sorbitol
dehydrogenase (SDH; Genzyme Diagnostics, Cambridge,
MA) were determined using a commercial kit by quanti-
fying the decrease in absorbance according to the manu-
facturer’s protocol. Assay results for both GLDH and
SDH were quantified using the Cobas Fara II clinical
chemistry analyzer (Roche Diagnostics, Indianapolis,
IN). Caspase-cleaved and total K18 were determined
using the M65 and M30 (apoptosense) ELISAs, re-
spectively, in accordance with the manufacturer’s
guidelines (Peviva, West Chester, OH). Total HMGB1
content was determined in serum by enzyme-linked
immunosorbent assay (ELISA) per the manufacturer’s
protocol (IBL International, Hamburg, Germany). For
all ELISA analytes, the inter- and intra-assay variability
was <10%.RNA isolation and miR-122 quantification
RNA isolation and miR-122 quantification were per-
formed according to a protocol published previously
[15], with the exception that 200μl serum was used
for RNA extraction. The expression levels of miRNA
hsa-miR-122 (miR-122) were quantified using the Taq-
Man miRNA reverse transcription kit and miRNA-
specific stem-loop primers (Applied Biosystems, Foster
City, CA) in a scaled-down (5μl) reverse-transcription
reaction as described by Kroh et al. [16], using the
7900HT instrument (Applied Biosystems). MiRNA was
quantified by absolute quantification via a standard
curve, with quantities normalized to an exogenous
spike-in control derived from Caenorhabditis elegans,
cel-miR-39.Figure 2 Alanine aminotransferase (ALT) measurement. Blood
was collected before dosing on day 1 (baseline), and days 2, 5, 10,
13, 16, 20, 24, and at end of the follow-up phase. Solid and dashed
lines represent placebo and moxifloxacin treatments, respectively.
EOS is End of Study. Values represent fold change over upper limit
of normal (ULN).Statistical analysis
Clinical biochemistry parameters were expressed as fold
change from upper limit of normal (ULN). Biomarker
values were expressed as post-dosing fold change com-
pared to the pre-dosing baseline. Cholestyramine-
mediated changes in the concentrations of biomarkers
in comparison to the pre-dosing concentrations were
assessed using paired one-tailed Student’s t-test. Bio-
marker correlation analyses were performed by calculating
the Pearson correlation coefficient (σ). Descriptive statis-
tics for liver-function tests and biomarkers included the
arithmetic mean, standard error of the mean (SEM),
and median. Differences in mean or correlation were
deemed significant when p < 0.05.Results
Clinical biochemistries
Of the 67 subjects who received placebo (and never re-
ceived active study medication) and were administered
cholestyramine, eleven subjects experienced asymptom-
atic elevations in serum ALT levels exceeding three-fold
the upper limit of normal (>3× ULN). Six of these sub-
jects had received the single oral dose of moxifloxacin
the day before the start of cholestyramine treatment.
The mean elevation was 255 U/L after treatment with
cholestyramine compared to pre-dosing mean ALT level
of 20 U/L. Four of the 11 subjects experienced peak ALT
levels >5× ULN (2 men and 2 women) and one of the
women experienced a 28-fold ULN increase (Figure 2).
This latter subject was a 31 year old Caucasian woman
with normal BMI (BMI = 25) taking oral contraceptives
concomitantly. Two other young women with ALT eleva-
tion <5× ULN were also taking oral contraceptives. How-
ever, oral contraceptives were given to most of young
women of child bearing potential in this trial and only
one woman described above experienced an increase in
ALT >5× ULN .
A rise in ALT levels was first evident three days after
starting cholestyramine (study day 16), and the peak
values were obtained 4 to 8 days later (between study
day 20 and 24) (Figure 2). The single dose of moxifloxa-
cin did not appear to influence the incidence or height
of the serum ALT elevations observed; indeed, three
subjects with the highest peak serum ALT values had
not received moxifloxacin (Figure 2). The serum ALT
rises were mirrored by elevations in serum AST (ρ =
0.99, P < 0.0001). The enzyme elevations were asymp-
tomatic in each subject, returning to normal ranges
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serum ALP or total bilirubin levels (Table 1) which indi-
cated that there was no clinical evidence of cholestasis.
Experimental biomarkers
Only the serum samples (baseline and peak) from sub-
jects who experienced elevations in serum ALT exceeding
3 × ULN were archived and assayed for experimental bio-
marker analysis (Figure 3). The mean serum level of the
liver-specific miRNA-122 [9] was elevated 22.4-fold over
baseline (P < 0.05); mean levels of necrosis biomarkers
SDH and HMGB1 [4,5,7,8,17] were elevated 8.1-, and 1.7
fold (P < 0.05), respectively over baseline. Mean serum
levels of full-length cytokeratin 18 (M65) rose 2.1 fold,
and its caspase-cleaved fragment (M30), a biomarker of
apoptosis [5,6], also rose 1.7 fold (P < 0.05), Figure 3).
Mean serum GLDH was elevated 7.3- fold. The single
dose of moxifloxacin received by 5 of 11 subjects did not
have any obvious influence on extent of elevation of any
of the biomarkers measured relative to placebo. The Pear-
son correlation coefficient of peak ALT levels was 0.87
with SDH, 0.45 with GLDH, 0.53 with miR-122, 0.31 with
cytokeratin 18, with a significant (P < 0.05) correlation ob-
served between ALT and SDH, GLDH and SDH, and
GLDH and full length K18 (Table 2). However, there was
no correlation observed between fold elevation in serum
ALT with fold elevation in caspase-cleaved K18 or
HMGB1. Data obtained for each subject are listed in Add-
itional file 3: Table S2.
Discussion
Serum alanine aminotransferase (ALT) has for more
than four decades been used in clinical trials as a sensi-
tive means to monitor liver safety of new drug candi-
dates. However, this biomarker lacks specificity and can
be elevated during treatment with drugs that are entirelyTable 1 Classical clinical chemistry parameters following chol
treated subjects
Subject# Treatment type ALT (U/L) baseline ALT (U/L) peak
1 Placebo 16 273
2 Placebo 19 320
3 Placebo 15 967
4 Placebo 18 119
5 Placebo 16 145
6 Placebo 12 146
7 Moxifloxacin 33 164
8 Moxifloxacin 32 173
9 Moxifloxacin 30 229
10 Moxifloxacin 14 142
11 Moxifloxacin 20 136
For ALT, both absolute peak value and ULN have been included. For AST, ALP, andsafe for the liver [1]. There is urgent need for new bio-
markers capable of distinguishing ALT elevations observed
in a clinical trial that represent a “false positive” – i.e., the
drug does not cause clinically significant hepatotox-
icity vs. a “true positive” – i.e., the drug has potential
to cause progressive and clinically important liver in-
jury. Cholestyramine has been used for the treatment
of hypercholesterolemia for more than fifty years and
this treatment has never been associated with clinic-
ally important liver injury. Hence, the marked eleva-
tions in serum ALT we observed during treatment
with cholestyramine represent a “false positive” safety
signal for this drug. In other words, if cholestyramine
were a new drug in early clinical development, the
profile of serum ALT elevations observed would likely
result in termination of the development program
over liver safety concerns although no true safety li-
ability exists. Our serum sample set obtained from
healthy adult volunteers treated with cholestyramine
therefore provided a means for investigating false positive
results using additional toxicity biomarkers that have been
proposed to represent advances in multiple respects over
traditional liver safety biomarkers.
The eleven healthy volunteers who experienced eleva-
tions in serum ALT during cholestyramine treatment
also had significant increases in serum miR-122. Circu-
lating miR-122 is reported to be essentially liver-specific
and has been established as a marker of drug-induced
liver injury in humans [9]. In fact, a recent rodent study
suggested a greater specificity and sensitivity of peak
serum miR-122 with the extent of liver necrosis as
judged histologically than that of peak serum ALT [18].
The marked rise in miR-122 we observed confirms at
least a substantial contribution of liver-specific injury to
the biomarker elevations we observed during cholestyr-
amine treatment. In addition, it is doubtful that miR-122estyramine administration in placebo- or moxifloxacin-
Peak ALT(ULN) AST (ULN) ALP (ULN) Total bilirubin (ULN)
6.1 1.8 1.0 0.6
9.4 3.6 0.7 0.4
28.4 10.9 0.9 0.6
3.5 1.9 0.7 0.5
4.3 2.6 0.6 0.8
4.3 2.6 0.6 0.4
3.6 1.8 1.1 0.3
3.8 2.0 0.6 0.5
5.1 2.7 1.4 0.9
3.2 1.5 0.7 0.9
4.0 1.9 0.8 0.4
total Bilirubin only ULN have been included.
Figure 3 Fold changes in investigational new biomarkers.
Values are mean ± SEM fold changes post vs pre cholestyramine
administration, N = 11, represented as fold change post-dosing
over pre-dosing.
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degradation or elimination in serum, indicating that accu-
mulation in serum due to reduced clearance is unlikely.
Cholestyramine treatment produced increases in mean
serum levels of GLDH, SDH, and HMGB1 which have
been proposed as specific indicators of necrosis [8,17].
SDH is located primarily in liver and kidney; activity of
SDH increases rapidly in acute episodes of liver necrosis
[19]. HMGB1 is a non-histone nuclear protein that is
abundant in the nucleus of cells [20]. The elevations we
observed in the serum levels of these biomarkers sup-
port the occurrence of hepatocellular necrosis, rather
than membrane blebbing or other mechanisms that
could result in cytosol leakage from viable hepatocytes.
We also observed a rise in the serum concentration of
caspase-cleaved cytokeratin18 fragments (M30) which
supports occurrence of hepatocellular apoptosis due to
cholestyramine administration [5,6]. Because it is pos-
sible for a toxic injury to result in apoptosis when suffi-
cient cellular ATP levels are maintained, but progress to





miR-122 0.53 0.39 0.11
K18 0.31 0.44 0.83*
Cleaved K18 −0.11 0.22 0.13
HMGB1 −0.16 0.08 −0.25
*Indicates significant correlation, P < 0.05.whether the ratio of cleaved to total cytokeratin 18 dif-
fered between those subjects with highest and lowest
levels of ALT or miR-122 levels. No differences were evi-
dent, (Additional file 4: Table S3) so a shift from apop-
tosis to necrosis with injury progression was not
supported by these data. The reasons why this low-level
and clinically insignificant injury never progresses to-
ward a more serious toxicity are not clear.
The mechanisms by which cholestyramine treatment
could cause mild hepatocyte necrosis/apoptosis, and why
this is without any clinical consequence was not the focus
of our study and remains unclear. Cholestyramine is nei-
ther metabolized nor absorbed from the GI tract so it
could not have a direct effect on the liver. We speculate
that the interruption of enterohepatic cycling of essential
fat-soluble molecules and/or bile acids by cholestyramine
may lead to alterations in membrane integrity or compen-
satory increase in bile acid synthesis, and this may in-
directly result in transient necrosis and activation of
apoptotic pathways. However, cholestyramine administra-
tion leading to increased bile acid synthesis has not been
associated with significant impacts on hepatocytes, which
appear to adapt to the change [21]. There is experimental
evidence that cholestyramine increases activation of c-
JUN N-terminal protein kinase (JNK) in the context of
acetaminophen overdose in mice, but this activation is not
present without the acetaminophen challenge [22]. Inter-
estingly, cholestyramine feeding alone did not alter
hepatocellular levels of glutathione, indicating that chole-
styramine itself does not elicit a pro-oxidant or injurious
response, even at high exposure levels comprising 2% of
the diet [22]. Bertolotti et al. observed that in vivo admin-
istration of cholestyramine induced a significant dose-
related increase of 7α-hydroxylation along with a decrease
in the concentrations of plasma cholesterol [23]. A de-
crease in the concentrations of circulating bile acids trig-
ger a disinhibition of cholesterol 7α -hydroxylase, also
known as CYP7A1, resulting in enhanced production of
bile acids and reduced level of cholesterol in hepatocytes.
Long term cholestyramine treatment also decreased the
intestinal expression of genes involved in drug transport,
cholesterol metabolism, and apoprotein synthesis - MRP2,arkers and ALT
miR-122 K18 Cleaved K18 HMGB1
0.53 0.31 −0.11 −0.16
0.39 0.44 0.22 0.08
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hepatic expression - HMG-CoA reductase, CYP7A1, LDL
receptor and LXRα genes [24,25]. How changes in the
lipid, cholesterol and bile acid flux and altered hepatic me-
tabolism by cholestyramine could rapidly translate into
hepatocyte death is unclear but the rise in serum GLDH
we observed may provide some insight. GLDH is a large
protein localized in the mitochondrial matrix; its presence
in blood reflects loss of mitochondrial integrity. Hence, it
could be concluded that rises in serum GLDH during liver
injury implicate mitochondrial dysfunction as a mecha-
nisms underlying the necrosis [26]. Certain bile acids have
been shown to cause mitochondrial dysfunction [27] and
this could provide a mechanistic link between interruption
in enterohepatic cycling, the proposed compensatory in-
crease in bile acid synthesis, and hepatocyte death. One
caveat is that our serum was not specifically prepared to
eliminate mitochondria prior to freezing, and our serum
samples underwent a freeze-thaw cycle which may have
caused damage to intact mitochondria with leakage of de-
tectable GLDH [26].
We have recently applied the same biomarkers used in
the current study to serum samples obtained in healthy
volunteers treated with various heparins [15]. Heparins,
like cholestyramine, are known to cause marked eleva-
tions in serum ALT and AST, but these elevations are
considered safe since heparins have not been reported to
cause clinically important liver injury. In the heparin
study, we also observed elevations in miR-122, serum
GLDH and HMGB1 and concluded that mild and transi-
ent hepatocellular necrosis was occurring. However, des-
pite the fact that the mean elevations of serum ALT and
miR-122 are comparable in both the heparin and current
cholestyramine studies, the serum HMGB1 level rose an
average of 6.3-fold baseline in the heparin study but only
a 1.7-fold increase was observed in the current study.
Since we had only single serum samples from each sub-
ject, we could not test the hypothesis that this apparent
discrepancy resulted from the kinetics of release and
clearance of HMGB1. It should also be noted that in
contrast to our current observations with cholestyr-
amine, we did not find any rise in caspase-cleaved
cytokeratin-18 (M-30) in the heparin study and con-
cluded that heparins do not cause apoptosis. Because lit-
tle HMGB1 is released from cells undergoing apoptosis
[28], a reasonable conclusion is that the component of
apoptosis caused by cholestyramine may in part explain
the relatively low levels of HMGB1 we observed.
An important question is whether the magnitude of
rise in the mechanistic biomarkers observed during be-
nign ALT elevations (due to heparin or cholestyramine)
is lower than would be observed during comparable
ALT elevations produced by drugs capable of causing se-
vere liver injury. If so, then there may be a threshold ofconcern that could be determined. Owing to the recent
discovery and validation efforts for these biomarkers,
standard ranges for human studies have not been estab-
lished and, thus, these biomarkers may be more informative
for determining tissue origin and gaining mechanistic
insight. A recent publication by Antoine et al. investigated
the same experimental liver injury biomarkers in the con-
text of acute acetaminophen-induced liver injury in the
clinic [29]. Comparison of the data from the acetamino-
phen study is complicated by the differences in dose, hos-
pital presentation times, and study enrollment times of
the acute injury patients. However, the values for serum
ALT, GLDH, M65, and M30 measured in the present cho-
lestyramine study were inclusive within the ranges ob-
served for patients who developed clinically significant
liver injury due to acetaminophen overdose (Additional
file 5: Table S4). The observation could be partially ex-
plained by differences in sample collection and instrumen-
tation between the two studies. However, this finding
appears to support the assertion that the magnitude of ele-
vation for GLDH, M65, and M30, does not strictly indi-
cate a potential for overt liver injury in a given patient or
study subject.
Conclusion
Our biomarker data support the conclusion that the eleva-
tion in serum aminotransferases that occurs as a result of
cholestyramine treatment reflects both necrosis and apop-
tosis of hepatocytes. This was an unexpected finding since
cholestyramine has never been reported to cause clinically
important liver injury. Caution must therefore be used
when interpreting elevations in these markers in the con-
text of assessing liver safety of new drug candidates in
clinical trials. We believe that the application of these and
other new biomarkers will have a future role in monitor-
ing liver safety in clinical trials but additional validation
studies with DILI negative and DILI positive compounds
in both nonclinical and clinical settings are needed.
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